Search

Your search keyword '"Rieder, Florian"' showing total 1,163 results

Search Constraints

Start Over You searched for: Author "Rieder, Florian" Remove constraint Author: "Rieder, Florian"
1,163 results on '"Rieder, Florian"'

Search Results

1. MFGE8 links absorption of dietary fatty acids with catabolism of enterocyte lipid stores through HNF4γ-dependent transcription of CES enzymes

4. Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor

5. Elafin Reverses Intestinal Fibrosis by Inhibiting Cathepsin S-Mediated Protease-Activated Receptor 2

9. Stricturing Crohn’s Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions

12. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

13. Postoperative Crohn’s Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection

14. Diagnosis of Inflammatory Bowel Disease–Associated Peripheral Arthritis: A Systematic Review

19. Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis

20. Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn’s Disease

23. The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis

27. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.

29. Fibrosis in IBD: from pathogenesis to therapeutic targets.

31. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies

33. Change in Biologic Class Promotes Endoscopic Remission Following Endoscopic Postoperative Crohn’s Disease Recurrence

34. The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study

38. Fibrosis: from mechanisms to medicines

44. S902 Assessing the Impact of Interval Duration Between Ileal Pouch Creation and Loop Ileostomy Closure on the Development of Subsequent Inflammatory Pouch Conditions in Patients with Ulcerative Colitis

45. S877 Diagnosis of Inflammatory Bowel Disease Associated Peripheral Arthritis: A Systematic Review

46. S1110 Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation in a Phase 1b Study of the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis

48. Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus

49. Anastomotic Configuration and Temporary Diverting Ileostomy Do Not Increase Risk of Anastomotic Stricture in Postoperative Crohn's Disease

50. Efficacy of Endoscopic Dilation of Gastroduodenal Crohn’s Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data

Catalog

Books, media, physical & digital resources